Non-Current Liabilities
Total Liabilities
Merck & Co. Total Liabilities decreased by 29.3% to $229.00M in Q1 2026 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalLower is better
VolatilityStable
First reportedQ4 2024
Last reportedQ1 2026May 4, 2026
How to read this metric
A rising trend may indicate aggressive expansion or liquidity pressure, while a declining trend suggests deleveraging and improved balance sheet health.
Detailed definition
This represents the aggregate sum of all current and non-current financial obligations owed by the company to external p...
Peer comparison
Used across all industries to assess the overall debt burden relative to equity and assets.
Metric ID:
total_liabilitiesHistorical Data
3 periods
| Q4 '24 | Q4 '25 | Q1 '26 | |
|---|---|---|---|
| Value | $538.00M | $324.00M | $229.00M |
| QoQ Change | — | -39.8% | -29.3% |
| YoY Change | — | -39.8% | — |
Range$229.00M – $538.00M
Avg YoY Growth-39.8%
Median YoY Growth-39.8%
Current Streak2+ quarters decline
Product Breakdown
| Segment | Q1 '23 | Q3 '23 | Q4 '23 | Q1 '24 |
|---|---|---|---|---|
| Alliance revenue - Lenvima | $125.00M | $250.00M | $250.00M | $125.00M |
| Total | — | — | — | — |
Alliance revenue - Lenvima was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Total Liabilities at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s total liabilities?
- Merck & Co. (MRK) reported total liabilities of $229.00M in Q1 2026.
- What does total liabilities mean?
- The total amount of money the company owes to all creditors and stakeholders.